Statins, ACE inhibitors and ARBs in cardiovascular disease

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 3, 2009, Pages 389-400

  Montecucco, Fabrizio ^a   Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

angiotensin II receptor blockers; angiotensin converting enzyme inhibitors; inflammation; statin

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; PERINDOPRIL; PITAVASTATIN; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ACUTE CORONARY SYNDROME; ANGIONEUROTIC EDEMA; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSLIPIDEMIA; HEART FAILURE; HEART INFARCTION; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER FAILURE; PERIPHERAL VASCULAR DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT;

ACUTE CORONARY SYNDROME; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 66549114922     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.12.003     Document Type: Review

References (124)

1. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104 (2001) 2746-2753
2. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 104 (2001) 2855-2864
3. American Heart Association. 2002 Heart and Stroke Statistical Update (2002), American Heart Association, Dallas, Tex
4. Ledford D.K., and Espinoza L.R. Immunologic aspects of cardiovascular disease. JAMA: The Journal of the American Medical Association 258 (1987) 2974-2982
5. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nature Reviews. Immunology 6 (2006) 508-519
6. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108 (2003) 1664-1672
7. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 108 (2003) 1772-1778
8. Stary H.C., Chandler A.B., Glagov S., et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89 (1994) 2462-2678
9. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92 (1995) 1355-1374
10. Fox K.A., Birkhead J., Wilcox R., et al. British Cardiac Society Working Group on the definition of myocardial infarction. Heart 90 (2004) 603-609
11. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Journal of the American College of Cardiology 50 (2007) 2173-2195
12. Capildeo R., Haberman S., and Rose F.C. The definition and classification of stroke. A new approach. The Quarterly Journal of Medicine 47 (1978) 177-196
13. Ovbiagele B., Kidwell C.S., and Saver J.L. Epidemiological impact in the United States of a tissue-based definition of transient ischemic attack. Stroke 34 (2003) 919-924
14. Jolicoeur E.M., Ohman E.M., Temple R., et al. Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. American Heart Journal 155 (2008) 435-444
15. Pohjasvaara T., Mäntylä R., Ylikoski R., et al. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke 31 (2000) 2952-2957
16. Leskinen Y., Salenius J.P., Lehtimäki T., et al. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. American Journal of Kidney Diseases 40 (2002) 472-479
17. Prugger C., Wellmann J., Heidrich J., et al. Cardiovascular risk factors and mortality in patients with coronary heart disease. European Journal of Epidemiology (2008) 10.1007/s10654-008-9291-x
18. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
19. Montecucco F., and Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford, England) (2008) 10.1093/rheumatology/ken395
20. Krebs M., Krssak M., Nowotny P., et al. Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 2153-2160
21. Randle P.J., Garland P.B., Hales C.N., et al. The glucose fatty acids cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
22. Shafrir E., and Raz I. Diabetes: mellitus or lipidus?. Diabetologia 46 (2003) 433-440
23. Tobert J.A., Bell G.D., Birtwell J., et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. The Journal of Clinical Investigation 69 (1982) 913-919
24. Tobert J.A., Hitzenberger G., Kukovetz W.R., et al. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis 41 (1982) 61-65
25. Hoeg J.M., and Brewer Jr. H.B. 3-Hydroxy-3-methylglutaryl - coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA: The Journal of the American Medical Association 258 (1987) 3532-3536
26. Illingworth D.R., and Bacon S. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. The American Journal of Cardiology 60 (1987) 33G-42G
27. Moride Y., Hegele R.A., Langer A., et al. Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. The Canadian Journal of Cardiology 24 (2008) 293-300
28. Neil H.A., DeMicco D.A., Luo D., et al., CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 29 (2006) 2378-2384
29. Sever P.S., Poulter N.R., Dahlöf B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
30. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery 45 (2007) 645-654 discussion 653-654
31. Knopp R.H., d'Emden M., Smilde J.G., et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006) 1478-1485
32. Thavendiranathan P., Bagai A., Brookhart M.A., et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 166 (2006) 2307-2313
33. Ridker P.M., Fonseca F.A., Genest J., et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. The American Journal of Cardiology 100 (2007) 1659-1664
34. Khush K.K., and Waters D.D. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. Journal of Cardiac Failure 12 (2006) 664-674
35. Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
36. Kjekshus J., Apetrei E., Barrios V., et al., CORONA Group. Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine 357 (2007) 2248-2261
37. Nishikawa H., Miura S., Zhang B., et al. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coronary Artery Disease 13 (2002) 377-381
38. Borghi C., Veronesi M., Prandin M.G., et al. Statins and blood pressure regulation. Current Hypertension Reports 3 (2001) 281-288
39. McFarlane S.I., Muniyappa R., Francisco R., et al. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 1451-1458
40. Inami N., Nomura S., Shouzu A., et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiology of Haemostasis and Thrombosis 36 (2007) 1-8
41. Kinlay S., Schwartz G.G., Olsson A.G., et al. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arteriosclerosis, Thrombosis, and Vascular Biology 28 (2008) 142-147
42. Vlachopoulos C., Aznaouridis K., Dagre A., et al. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. European Heart Journal 28 (2007) 2102-2109
43. Blanco-Colio L.M., Martín-Ventura J.L., de Teresa E., et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American Heart Journal 153 (2007) 881-888
44. Pignatelli P., Sanguigni V., Lenti L., et al. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. Journal of Thrombosis and Haemostasis 5 (2007) 1170-1178
45. Hanefeld M., Marx N., Pfützner A., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. Journal of the American College of Cardiology 49 (2007) 290-297
46. Goicoechea M., de Vinuesa S.G., Lahera V., et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology 17 (2006) S231-S235
47. Patti G., Chello M., Pasceri V., et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. Journal of the American College of Cardiology 48 (2006) 1560-1566
48. Muhlestein J.B., May H.T., Jensen J.R., et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology 48 (2006) 396-401
49. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. Journal of the American College of Cardiology 47 (2006) 332-337
50. Macin S.M., Perna E.R., Farías E.F., et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. American Heart Journal 149 (2005) 451-457
51. Blanco-Colio L.M., Martín-Ventura J.L., de Teresa E., et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arteriosclerosis, Thrombosis, and Vascular Biology 27 (2007) 168-174
52. Arnaud C., Braunersreuther V., and Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends in Cardiovascular Medicine 15 (2005) 202-206
53. Spring S., Simon R., van der Loo B., et al. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thrombosis and Haemostasis 99 (2008) 182-189
54. Mäki-Petäjä K.M., Booth A.D., Hall F.C., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. Journal of the American College of Cardiology 50 (2007) 852-858
55. Crouse III J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA: The Journal of the American Medical Association 297 (2007) 1344-1353
56. Marchesi S., Lupattelli G., Siepi D., et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. Journal of Cardiovascular Pharmacology 36 (2000) 617-621
57. Eichstädt H.W., Eskötter H., Hoffman I., et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. The American Journal of Cardiology 76 (1995) 122A-125A
58. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89 (1994) 2519-2524
59. Ott C., Schlaich M.P., Schmidt B.M., et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 196 (2008) 704-711
60. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104 (2001) 249-252
61. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
62. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA: The Journal of the American Medical Association 282 (1999) 2340-2346
63. Davignon J., and Leiter L.A. Ongoing clinical trials of the pleiotropic effects of statins. Vascular Health and Risk Management 1 (2005) 29-40
64. Pitt B., Waters D., Brown W.V., et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. The New England Journal of Medicine 341 (1999) 70-76
65. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 352 (2005) 1425-1435
66. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA: The Journal of the American Medical Association 294 (2005) 2437-2445
67. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA: The Journal of the American Medical Association 285 (2001) 1711-1718
68. Liem A.H., van Boven A.J., Veeger N.J., et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. European Heart Journal 23 (2002) 1931-1937
69. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA: The Journal of the American Medical Association 292 (2004) 1307-1316
70. Ray K.K., Cannon C.P., Cairns R., et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology 46 (2005) 1417-1424
71. Ovbiagele B., and Saver J.L. Intensive statin therapy after stroke or transient ischemic attack: a SPARCLing success?. Stroke 38 (2007) 1110-1112
72. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
73. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs 67 Suppl. 1 (2007) 43-54
74. Robinson J.G., Smith B., Maheshwari N., et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. Journal of the American College of Cardiology 46 (2005) 1855-1862
75. Josan K., and McAlister F.A. Cholesterol lowering for secondary prevention: what statin dose should we use?. Vascular Health and Risk Management 3 (2007) 615-627
76. Hennekens C.H., Hollar D., Eidelman R.S., et al. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. Medscape General Medicine 8 (2006) 54
77. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
78. Neuvonen P.J., Backman J.T., and Niemi M. Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. Clinical Pharmacokinetics 47 (2008) 463-474
79. Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114 (2006) 2788-2797
80. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. Journal of Internal Medicine 260 (2006) 305-319
81. Chappell M.C. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension 50 (2007) 596-599
82. Schmieder R.E., Hilgers K.F., Schlaich M.P., et al. Renin-angiotensin system and cardiovascular risk. Lancet 369 (2007) 1208-1219
83. Donoghue M., Hsieh F., Baronas E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research 87 (2000) E1-E9
84. Tikellis C., Cooper M.E., and Thomas M.C. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. The International Journal of Biochemistry & Cell Biology 38 (2006) 737-751
85. Rizzoni D., and Agabiti Rosei E. Small artery remodeling in hypertension and diabetes. Current Hypertension Reports 8 (2006) 90-95
86. Connelly K.A., Boyle A.J., and Kelly D.J. Angiotensin II and the cardiac complications of diabetes mellitus. Current Pharmaceutical Design 13 (2007) 2721-2729
87. Clermont A., Bursell S.E., and Feener E.P. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. Journal of Hypertension. Supplement 24 (2006) S73-S80
88. Ichihara A., Hayashi M., Hirota N., et al. Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells. Hypertension Research 26 (2003) 915-921
89. Apostolakis S., Krambovitis E., Vlata Z., et al. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. Thrombosis Research 121 (2007) 387-395
90. Inukai T., Yoshida N., Wakabayashi S., et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus. The American Journal of the Medical Sciences 329 (2005) 222-227
91. Schupp M., Janke J., Clasen R., et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
92. Janke J., Schupp M., Engeli S., et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. Journal of Hypertension 24 (2006) 1809-1816
93. Jia N., Okamoto H., Shimizu T., et al. A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression. Hypertension Research 26 (2003) 737-742
94. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The New England Journal of Medicine 342 (2000) 145-153
95. Fox K.M., and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
96. Solomon S.D., Rice M.M., Jablonski K., et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 114 (2006) 26-31
97. DREAM Trial Investigators, Bosch J., Yusuf S., Gerstein H.C., et al. Effect of ramipril on the incidence of diabetes. The New England Journal of Medicine 355 (2006) 1551-1562
98. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA: The Journal of the American Medical Association 288 (2002) 2998-3007
99. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
100. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345 (1995) 669-685
101. Rutherford J.D., Pfeffer M.A., Moyé L.A., et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 90 (1994) 1731-1738
102. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. The New England Journal of Medicine 333 (1995) 1670-1676
103. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine 358 (2008) 1547-1559
104. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
105. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension 21 (2003) 875-886
106. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
107. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
108. McMurray J., Solomon S., Pieper K., et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology 47 (2006) 726-733
109. Dickstein K., Kjekshus J., and OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
110. Krum H., Carson P., Farsang C., et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. European Journal of Heart Failure 6 (2004) 937-945
111. Diener H.C., Sacco R., Yusuf S., Steering Committee, and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases (Basel, Switzerland) 23 (2007) 368-380
112. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
113. Khan N.A., Hemmelgarn B., Herman R.J., et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. The Canadian Journal of Cardiology 24 (2008) 465-475
114. Viberti G. Regression of albuminuria: latest evidence for a new approach. Journal of Hypertension. Supplement 21 (2003) S24-S28
115. Hasslacher C., Kempe H.P., and Bostedt-Kiesel A. ACE inhibitors and diabetic nephropathy: clinical and experimental findings. The Clinical Investigator 71 5 Suppl. (1993) S20-S24
116. Parving H.H., Andersen S., Jacobsen P., et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminars in Nephrology 24 (2004) 147-157
117. MacKinnon M., Shurraw S., Akbari A., et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. American Journal of Kidney Diseases 48 (2006) 8-20
118. Deferrari G., Ravera M., Deferrari L., et al. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. Journal of the American Society of Nephrology 13 Suppl. 3 (2002) S224-S229
119. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes & Metabolism 30 (2004) 487-496
120. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes & Metabolism 30 (2004) 498-505
121. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). Journal of the American College of Cardiology 44 (2004) E1-E211
122. Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, American Heart Association, Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 51 (2008) 210-247
123. AHA, ACC, National Heart, Lung, and Blood Institute, Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. Journal of the American College of Cardiology 47 (2006) 2130-2139
124. Lakhdar R., Al-Mallah M.H., and Lanfear D.E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. Journal of Cardiac Failure 14 (2008) 181-188